Starting with the protocol and patient enrollment in WP1, which was presented by the clinical trial lead, the Medical University of Vienna as well as Clinres Farmacija, the partners discussed regulatory affairs (WP2) – presented by Mihaela Peric (UZSM) and Bernhard Liegl from the newly added partner QBEX. Then, Professor Windhager from MUW presented the results of the OSTEOGROW study, before Professor Vukicevic gave a general summary of the basic concepts and preclinical results of OSTEOproSPINE.Īfter this overview, it was time to discuss the progress achieved in the different work packages during the first eleven months of the project. Gancberg presenting the new framework programme of the EC, Horizon Europe. David Gancberg, EC Project Officer, attended the meeting and gave valuable advice to the partners as well as an outlook on the Horizon Europe programme. On the premises of the Croatian Academy of Sciences and Arts in the heart of Zagreb, the partners found perfect conditions to discuss the project progress and define the next steps to take. On November 22-23, the OSTEOproSPINE consortium followed the invitation of their coordinator, Professor Slobodan Vukicevic (UZSM), and met in the capital of Croatia for their first progress and investigators meeting. OSTEOproSPINE: Successful first progress meeting in the heart of Zagreb
0 kommentar(er)
